COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

Search

Hims & Hers Health Inc

Geschlossen

BrancheKonsumgüter defensiv

64.47 10.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

57.38

Max

64.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

23M

49M

Verkäufe

105M

586M

KGV

Branchendurchschnitt

81.191

42.52

EPS

0.2

Gewinnspanne

8.444

Angestellte

1,637

EBITDA

39M

58M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-25.56% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.2B

12B

Vorheriger Eröffnungskurs

54.32

Vorheriger Schlusskurs

64.47

Nachrichtenstimmung

By Acuity

20%

80%

16 / 151 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Hims & Hers Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2025, 12:54 UTC

Wichtige Markttreiber

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4. Apr. 2025, 22:38 UTC

Heiße Aktien

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1. Apr. 2025, 23:15 UTC

Wichtige Markttreiber

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25. Feb. 2025, 15:33 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18. Nov. 2024, 19:07 UTC

Wichtige Markttreiber

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14. Okt. 2024, 15:02 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3. Okt. 2024, 11:28 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6. Mai 2025, 14:24 UTC

Ergebnisse

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30. Apr. 2025, 09:30 UTC

Top News

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2. Apr. 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21. Feb. 2025, 23:20 UTC

Ergebnisse

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19. Dez. 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19. Dez. 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19. Dez. 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16. Dez. 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16. Dez. 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3. Okt. 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 11:45 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 10:14 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2. Aug. 2024, 17:52 UTC

Akquisitionen, Fusionen, Übernahmen

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26. Juni 2024, 11:00 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24. Mai 2024, 20:37 UTC

Ergebnisse

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Peer-Vergleich

Kursveränderung

Hims & Hers Health Inc Prognose

Kursziel

By TipRanks

-25.56% Nachteil

12-Monats-Prognose

Durchschnitt 45.5 USD  -25.56%

Hoch 85 USD

Tief 25 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hims & Hers Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

14 ratings

4

Buy

8

Halten

2

Sell

Technischer Score

By Trading Central

36.685 / 52.35Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

16 / 151 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.